Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499851 | 0.95 | TDP1 (0.39) | ALDH1A1KDM4EGAATDP1HPGD | |
| SCHEMBL24418002 | 0.90 | TDP1 (0.39) | ALDH1A1KDM4EGAATDP1NPC1 | |
| SCHEMBL23645657 | 0.90 | TDP1 (0.42) | ALDH1A1KDM4EGAATDP1HPGD | |
| SCHEMBL23625408 | 0.82 | PIK3CA (0.37) | NPC1 | |
| SCHEMBL22423829 | 0.79 | TDP1 (0.49) | ALDH1A1KDM4EGAATDP1NPC1 | |
| SCHEMBL22423828 | 0.79 | TDP1 (0.49) | ALDH1A1KDM4EGAATDP1NPC1 | |
| SCHEMBL22423823 | 0.79 | TDP1 (0.49) | ALDH1A1KDM4EGAATDP1NPC1 | |
| SCHEMBL26038969 | 0.77 | CHRM2 (0.38) | ALDH1A1KDM4EGAAHPGDOGA | |
| SCHEMBL13799418 | 0.74 | ALDH1A1 (0.42) | ALDH1A1KDM4EGAATDP1NPC1 | |
| SCHEMBL23625387 | 0.73 | PIK3CA (0.38) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | GLA, BACE1, GAA | ALDH1A1 142/4885KDM4E 2919/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.